Italy

Italy

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
0.71 (0.62 - 0.80) 2019 Modelled IHME
0.71 (0.62 - 0.80) 2018 Modelled IHME
0.72 (0.62 - 0.80) 2017 Modelled IHME
0.74 (0.64 - 0.82) 2016 Modelled IHME
0.76 (0.67 - 0.85) 2015 Modelled IHME
0.78 (0.69 - 0.87) 2014 Modelled IHME
0.8 (0.71 - 0.89) 2013 Modelled IHME
0.82 (0.72 - 0.91) 2012 Modelled IHME
0.83 (0.74 - 0.92) 2011 Modelled IHME
0.85 (0.75 - 0.95) 2010 Modelled IHME
0.87 (0.77 - 0.96) 2009 Modelled IHME
0.89 (0.80 - 0.99) 2008 Modelled IHME
0.91 (0.81 - 1.01) 2007 Modelled IHME
0.93 (0.83 - 1.03) 2006 Modelled IHME
0.95 (0.85 - 1.05) 2005 Modelled IHME
0.96 (0.86 - 1.06) 2004 Modelled IHME
0.98 (0.87 - 1.08) 2003 Modelled IHME
0.99 (0.89 - 1.09) 2002 Modelled IHME
1 (0.90 - 1.11) 2001 Modelled IHME
1.02 (0.92 - 1.13) 2000 Modelled IHME
1.04 (0.93 - 1.15) 1999 Modelled IHME
1.06 (0.96 - 1.17) 1998 Modelled IHME
1.09 (0.98 - 1.19) 1997 Modelled IHME
1.11 (1.01 - 1.22) 1996 Modelled IHME
1.14 (1.03 - 1.24) 1995 Modelled IHME
1.16 (1.05 - 1.27) 1994 Modelled IHME
1.18 (1.06 - 1.30) 1993 Modelled IHME
1.2 (1.08 - 1.32) 1992 Modelled IHME
1.22 (1.10 - 1.35) 1991 Modelled IHME
1.24 (1.11 - 1.38) 1990 Modelled IHME
0.7 (0.40 - 1) 2016 Modelled ECDC
0.5 (0.30 - 1) 2007 Survey/reported Cozzolongo R et al, 2009
0.8 (0.40 - 1.30) 2003 Survey/reported Pendino GM, 2005
0.7 (0 - 3.90) 2001 Survey/reported Floreani A, 2006
1.7 (0.90 - 2.90) 2014 Survey/reported Morisco, 2017
1.67 (1.26 - 2.17) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.03 (0.02 - 0.03) 2019 Modelled IHME
0.03 (0.02 - 0.03) 2018 Modelled IHME
0.03 (0.02 - 0.03) 2017 Modelled IHME
0.03 (0.02 - 0.03) 2016 Modelled IHME
0.03 (0.02 - 0.03) 2015 Modelled IHME
0.03 (0.02 - 0.03) 2014 Modelled IHME
0.03 (0.02 - 0.03) 2013 Modelled IHME
0.03 (0.02 - 0.03) 2012 Modelled IHME
0.03 (0.02 - 0.03) 2011 Modelled IHME
0.03 (0.02 - 0.03) 2010 Modelled IHME
0.03 (0.02 - 0.03) 2009 Modelled IHME
0.03 (0.02 - 0.03) 2008 Modelled IHME
0.03 (0.02 - 0.04) 2007 Modelled IHME
0.03 (0.02 - 0.04) 2006 Modelled IHME
0.03 (0.02 - 0.04) 2005 Modelled IHME
0.03 (0.02 - 0.04) 2004 Modelled IHME
0.03 (0.02 - 0.04) 2003 Modelled IHME
0.03 (0.02 - 0.04) 2002 Modelled IHME
0.03 (0.02 - 0.04) 2001 Modelled IHME
0.03 (0.03 - 0.04) 2000 Modelled IHME
0.04 (0.03 - 0.05) 1999 Modelled IHME
0.04 (0.03 - 0.06) 1998 Modelled IHME
0.05 (0.04 - 0.06) 1997 Modelled IHME
0.06 (0.05 - 0.07) 1996 Modelled IHME
0.07 (0.05 - 0.09) 1995 Modelled IHME
0.08 (0.06 - 0.10) 1994 Modelled IHME
0.1 (0.08 - 0.13) 1993 Modelled IHME
0.13 (0.10 - 0.16) 1992 Modelled IHME
0.16 (0.12 - 0.20) 1991 Modelled IHME
0.19 (0.14 - 0.24) 1990 Modelled IHME
0.61 (0.39 - 0.93) 2015 Modelled WHO
Showing out of
Show more
Pregnant women
Download
Value (%) Year Type Source
0.8 (0.70 - 1) 2016 Modelled ECDC
0.9 (0.70 - 1) 2009 Survey/reported Spada E et al, 2014
0.8 (0.60 - 1) 2012 Survey/reported Ruffini E et al, 2014
Showing out of
Show more
Prisoners
Download
Value (%) Year Type Source
6.7 (5.20 - 8.40) 2002 Survey/reported Babudieri S et al, 2005

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
9 (8 - 11) 2019 Modelled IHME
9 (8 - 11) 2018 Modelled IHME
9 (8 - 11) 2017 Modelled IHME
9 (8 - 11) 2016 Modelled IHME
9 (8 - 10) 2015 Modelled IHME
9 (8 - 10) 2014 Modelled IHME
9 (8 - 10) 2013 Modelled IHME
9 (8 - 10) 2012 Modelled IHME
9 (8 - 10) 2011 Modelled IHME
9 (8 - 10) 2010 Modelled IHME
9 (8 - 11) 2009 Modelled IHME
9 (8 - 11) 2008 Modelled IHME
9 (8 - 11) 2007 Modelled IHME
9 (8 - 11) 2006 Modelled IHME
9 (8 - 11) 2005 Modelled IHME
10 (8 - 11) 2004 Modelled IHME
10 (8 - 12) 2003 Modelled IHME
10 (8 - 12) 2002 Modelled IHME
10 (8 - 12) 2001 Modelled IHME
10 (9 - 12) 2000 Modelled IHME
10 (9 - 13) 1999 Modelled IHME
11 (9 - 13) 1998 Modelled IHME
11 (9 - 13) 1997 Modelled IHME
11 (9 - 13) 1996 Modelled IHME
11 (9 - 13) 1995 Modelled IHME
11 (9 - 13) 1994 Modelled IHME
11 (9 - 13) 1993 Modelled IHME
11 (9 - 14) 1992 Modelled IHME
12 (10 - 14) 1991 Modelled IHME
12 (10 - 14) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
95 2018 Survey/reported WHO/UNICEF
94 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
93 2015 Survey/reported WHO/UNICEF
95 2014 Survey/reported WHO/UNICEF
96 2013 Survey/reported WHO/UNICEF
96 2012 Survey/reported WHO/UNICEF
96 2011 Survey/reported WHO/UNICEF
96 2010 Survey/reported WHO/UNICEF
96 2009 Survey/reported WHO/UNICEF
96 2008 Survey/reported WHO/UNICEF
97 2007 Survey/reported WHO/UNICEF
96 2006 Survey/reported WHO/UNICEF
96 2005 Survey/reported WHO/UNICEF
96 2004 Survey/reported WHO/UNICEF
95 2003 Survey/reported WHO/UNICEF
95 2002 Survey/reported WHO/UNICEF
95 2001 Survey/reported WHO/UNICEF
94 2000 Survey/reported WHO/UNICEF
97 1999 Survey/reported WHO/UNICEF
95 1998 Survey/reported WHO/UNICEF
95 1997 Survey/reported WHO/UNICEF
95 1996 Survey/reported WHO/UNICEF
95 1995 Survey/reported WHO/UNICEF
95 1994 Survey/reported WHO/UNICEF
95 1993 Survey/reported WHO/UNICEF
95 1992 Survey/reported WHO/UNICEF
95 1991 Survey/reported WHO/UNICEF
Showing out of
Show more

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
30 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.78 (1.44 - 2.19) 2019 Modelled IHME
1.77 (1.44 - 2.18) 2018 Modelled IHME
1.76 (1.42 - 2.16) 2017 Modelled IHME
1.72 (1.39 - 2.11) 2016 Modelled IHME
1.7 (1.37 - 2.07) 2015 Modelled IHME
1.72 (1.39 - 2.10) 2014 Modelled IHME
1.78 (1.44 - 2.18) 2013 Modelled IHME
1.86 (1.51 - 2.28) 2012 Modelled IHME
1.93 (1.56 - 2.35) 2011 Modelled IHME
1.96 (1.59 - 2.39) 2010 Modelled IHME
1.96 (1.60 - 2.39) 2009 Modelled IHME
1.96 (1.60 - 2.39) 2008 Modelled IHME
1.97 (1.60 - 2.39) 2007 Modelled IHME
1.97 (1.61 - 2.39) 2006 Modelled IHME
1.97 (1.61 - 2.39) 2005 Modelled IHME
2.02 (1.65 - 2.44) 2004 Modelled IHME
2.11 (1.73 - 2.55) 2003 Modelled IHME
2.22 (1.81 - 2.68) 2002 Modelled IHME
2.32 (1.89 - 2.80) 2001 Modelled IHME
2.35 (1.92 - 2.84) 2000 Modelled IHME
2.35 (1.92 - 2.84) 1999 Modelled IHME
2.35 (1.91 - 2.83) 1998 Modelled IHME
2.34 (1.91 - 2.83) 1997 Modelled IHME
2.33 (1.90 - 2.82) 1996 Modelled IHME
2.32 (1.89 - 2.81) 1995 Modelled IHME
2.29 (1.87 - 2.77) 1994 Modelled IHME
2.22 (1.82 - 2.69) 1993 Modelled IHME
2.13 (1.74 - 2.58) 1992 Modelled IHME
2.03 (1.65 - 2.46) 1991 Modelled IHME
1.91 (1.56 - 2.32) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

National
Download
Value (%) Year Type Source
5.9 (5.20 - 6.60) 2016 Modelled ECDC
3 (2.20 - 4.10) 2014 Survey/reported Morisco, 2017
2.6 (2 - 3.40) 2007 Survey/reported Cozzolongo R et al, 2009
6.5 (5.40 - 7.80) 2003 Survey/reported Pendino GM, 2005
10.2 (8 - 12.70) 2001 Survey/reported Floreani A, 2006
2 (1.60 - 7.30) 2014 Modelled Gower et al, 2014
Showing out of
Show more
People who inject drugs (PWID)
Download
Value (%) Year Type Source
57.9 (52.50 - 63.30) 2014 Modelled Degenhardt L et al, 2017
60.5 (56.80 - 64) 2010 Survey/reported EMCDDA
Showing out of
Show more
Pregnant women
Download
Value (%) Year Type Source
0.4 (0.30 - 0.50) 2012 Survey/reported Ruffini E et al, 2014
Prisoners
Download
Value (%) Year Type Source
38 (35 - 41.20) 2002 Survey/reported Babudieri S et al, 2005

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
58 (54 - 62) 2019 Modelled IHME
58 (54 - 62) 2018 Modelled IHME
58 (54 - 62) 2017 Modelled IHME
57 (53 - 61) 2016 Modelled IHME
57 (53 - 61) 2015 Modelled IHME
57 (53 - 61) 2014 Modelled IHME
57 (53 - 61) 2013 Modelled IHME
57 (53 - 61) 2012 Modelled IHME
57 (53 - 61) 2011 Modelled IHME
57 (53 - 61) 2010 Modelled IHME
57 (53 - 61) 2009 Modelled IHME
57 (53 - 61) 2008 Modelled IHME
57 (53 - 61) 2007 Modelled IHME
57 (53 - 60) 2006 Modelled IHME
56 (52 - 60) 2005 Modelled IHME
56 (52 - 60) 2004 Modelled IHME
56 (52 - 60) 2003 Modelled IHME
55 (51 - 60) 2002 Modelled IHME
55 (51 - 59) 2001 Modelled IHME
55 (51 - 59) 2000 Modelled IHME
54 (50 - 59) 1999 Modelled IHME
54 (50 - 59) 1998 Modelled IHME
55 (50 - 59) 1997 Modelled IHME
55 (50 - 59) 1996 Modelled IHME
54 (50 - 59) 1995 Modelled IHME
54 (50 - 59) 1994 Modelled IHME
54 (50 - 58) 1993 Modelled IHME
54 (50 - 58) 1992 Modelled IHME
54 (50 - 58) 1991 Modelled IHME
54 (49 - 58) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Percent of PWID accessing OST

People who inject drugs (PWID)
Download
Value (%) Year Type Source
30 2017 Survey/reported EMCDDA, 2019
HBV National Action Plan
HBV elimination goal
HepB birth dose policy
Yes (for risk groups)
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
Yes
% of substance use disorder facilities offering hepatitis testing
Many (31-60%)
% of substance use disorder facilities offering hepatitis treatment
Some (11-30%)

Overview

HBV elimination goal
HCV elimination goal

Prevalence (national)

Modelled

HBV (HBsAg+)
0.71 (%)
2019
(0.62 - 0.8(%))
IHME
HCV (RNA/cAg+)
1.78 (%)
2019
(1.44 - 2.19(%))
IHME

Survey/surveillance

HBV (HBsAg+)
1.7 (%)
2014
(0.9 - 2.9(%))
Morisco, 2017
HCV (anti-HCV)
3 (%)
2014
(2.2 - 4.1(%))
Morisco, 2017

Hepatitis related deaths (national)

Modelled

HBV
1,714
2019
(1,517 - 1,927)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
8,050
2019
(7,096 - 8,856)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.03 (%)
2019, latest modelled
(0.02 - 0.03(%))
IHME

Prevalence PWID

HCV
60.50 (%)
2010, survey/surveillance
(56.80 - 64(%))
EMCDDA

Birth dose vaccination coverage (national)

Survey/surveillance

No data available

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines

Resources